Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel

OBJECTIVE: Perampanel, a selective, noncompetitive α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) glutamate receptor antagonist, is indicated for adjunctive treatment of partial seizures in patients ≥12 years based on three phase III clinical studies. The perampanel U.S. Prescribing Inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Ettinger, Alan B., LoPresti, Antonia, Yang, Haichen, Williams, Betsy, Zhou, Sharon, Fain, Randi, Laurenza, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758397/
https://www.ncbi.nlm.nih.gov/pubmed/26140524
http://dx.doi.org/10.1111/epi.13054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758397/
https://www.ncbi.nlm.nih.gov/pubmed/26140524
http://dx.doi.org/10.1111/epi.13054

Ejemplares similares